



## **AGUETTANT continues international development by setting up in Germany**

**Laboratoire AGUETTANT announces the opening of a new subsidiary in Germany. Since January 2016, they have been selling a range of innovative injectable medicines on the largest European pharmaceutical market.**

The newly-established German subsidiary offers the products from the French company specialising in essential injectable medicines on the German and Austrian markets. Conquering these markets begins with marketing the first pre-filled syringes used in anaesthesia. AGUETTANT is the only pharmaceutical company in Europe to offer this range of products.

This new team of 6, based in Langenfeld (between Düsseldorf and Cologne), strengthens AGUETTANT's commitment to providing healthcare professionals with innovative products for hospital use. AGUETTANT's pre-filled syringes respond to unmet medical needs, encouraging healthcare professionals to optimise their practices while also helping to preserve the lives of many patients. In the near future, more AGUETTANT medical products will be available in Germany.

### **A market with huge potential**

Germany is now the primary European market for medicines, and the fourth on the global market. With 81.8 million inhabitants, Germany is the largest market in Europe.

This development in Germany is part of AGUETTANT's business strategy to become a recognised European player.

This new facility is the fourth subsidiary of the AGUETTANT Group which intends to continue this structuring on big European and worldwide pharmaceutical markets. Between now and mid-2016, two new branches will begin operating in Spain and Italy. In the next ten years, Laboratoire AGUETTANT aims to make a turnover of €200 million in Europe.

These facilities alone will complement AGUETTANT's ground presence in France | Belgium | the United Kingdom | Vietnam. This serves as a platform for development in Asia; AGUETTANT's next venture after Europe.

### **About Aguettant**

Laboratoire Aguettant SAS is a pharmaceutical company dedicated to the development, manufacturing and commercialization of essential hospital medicines. Its expertise in developing innovative injectable drugs makes Aguettant a duly recognized player in critical care, anesthesiology, micronutrients and neurology. The company has a strong commercial infrastructure in Europe through its subsidiaries and elsewhere in the world through its international distributors.